Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Proposes Medicare Part D Drugs For Duals Be Reimbursed At Medicaid Rates

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposal offered by Senate Finance Committee chairman in health care reform white paper follows path Rep. Waxman is expected to take with legislation early next year.

You may also be interested in...



Obama Taps Daschle, Lambrew To Lead New White House Health Care Reform Office

The announcement came with Tom Daschle’s nomination as HHS secretary at a Dec. 11 press conference by the president-elect.

Obama Taps Daschle, Lambrew To Lead New White House Health Care Reform Office

The announcement came with Tom Daschle’s nomination as HHS secretary at a Dec. 11 press conference by the president-elect.

Sen. Enzi’s Bid For Finance Cmte. Post Could Create Key Broker On Health Reform

Enzi, the ranking member on the Health Committee, would be one of three senators on both of the committees with jurisdiction over coverage issues.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel